<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Cancer</journal-title></journal-title-group><issn pub-type="ppub">0008-543X</issn><issn pub-type="epub">1097-0142</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4977021</article-id><article-id pub-id-type="pmcid-ver">PMC4977021.1</article-id><article-id pub-id-type="pmcaid">4977021</article-id><article-id pub-id-type="pmcaiid">4977021</article-id><article-id pub-id-type="manuscript-id">NIHMS806262</article-id><article-id pub-id-type="pmid">21717444</article-id><article-id pub-id-type="doi">10.1002/cncr.26292</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS806262</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA806262</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Phase II Randomized Study of p53 Antisense Oligonucleotide (Cenersen) plus Idarubicin With or Without Cytarabine in Refractory and Relapsed Acute Myeloid Leukemia</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Cortes</surname><given-names initials="J">J</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kantarjian</surname><given-names initials="H">H</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ball</surname><given-names initials="ED">E D</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>DiPersio</surname><given-names initials="J">J</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kolitz</surname><given-names initials="JE">J E</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fernandez</surname><given-names initials="HF">H F</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goodman</surname><given-names initials="M">M</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Borthakur</surname><given-names initials="G">G</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Baer</surname><given-names initials="MR">Maria R</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A6">6</xref><xref rid="FN2" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wetzler</surname><given-names initials="M">Meir</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A6">6</xref></contrib></contrib-group><aff id="A1"><label>1</label>MD Anderson Cancer Center, Houston, Texas</aff><aff id="A2"><label>2</label>University of California San Diego, LaJolla, California</aff><aff id="A3"><label>3</label>Washington University, St. Louis, Missouri</aff><aff id="A4"><label>4</label>North Shore University Hospital, Manhasset, New York</aff><aff id="A5"><label>5</label>University of Miami, Miami, Florida</aff><aff id="A6"><label>6</label>Roswell Park Cancer Institute, Buffalo, New York</aff><author-notes><corresp id="FN1">Address correspondence and reprint requests to: Jorge Cortes, MD, Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 428, Houston, TX 77030, Phone: 713-794-5783, Fax: 713-794-4297, <email>jcortes@mdanderson.org</email></corresp><fn id="FN2" fn-type="present-address"><label>*</label><p>Current address: University of Maryland Greenbaum Cancer Center, Baltimore, Maryland</p></fn></author-notes><pub-date pub-type="epub"><day>29</day><month>6</month><year>2011</year></pub-date><pub-date pub-type="ppub"><day>15</day><month>1</month><year>2012</year></pub-date><volume>118</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">273787</issue-id><fpage>418</fpage><lpage>427</lpage><pub-history><event event-type="nihms-submitted"><date><day>02</day><month>08</month><year>2016</year></date></event><event event-type="pmc-release"><date><day>08</day><month>08</month><year>2016</year></date></event><event event-type="pmc-live"><date><day>08</day><month>08</month><year>2016</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-05 14:06:38.133"><day>05</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms806262.pdf"/><abstract><sec id="S1"><title>Background</title><p id="P1">The p53 antisense oligonucleotide cenersen has been shown to sensitize acute myeloid leukemia (AML) stem cells to DNA damaging agents.</p></sec><sec id="S2"><title>Methods</title><p id="P2">To determine if cenersen merits testing in larger efficacy studies, an exploratory study of cenersen in combination with idarubicin either alone or with one of two doses of cytarabine was performed in first salvage AML patients. Patients who either had failed to respond to a single induction course or had responded to induction but relapsed within 12 months were enrolled. Stopping rules based on an expected 14% complete response (CR) rate were applied to each treatment arm.</p></sec><sec id="S3"><title>Results</title><p id="P3">Fifty-three patients were treated and none of the arms was terminated for lack of activity. Nearly all patients received a single course unless they responded. Ten of the 53 (19%) patients responded (8 CR and 2 CR with incomplete platelet recovery [CRp]). There was a positive trend for a better response rate with increasing intensity of chemotherapy in the patients refractory to frontline treatment compared to those who had previously relapsed. One-third (17/53) of the patients received cenersen inhibitors (acetaminophen and/or high dose antioxidants) during treatment and none of these responded to treatment. No unique toxicity was attributed to cenersen.</p></sec><sec id="S4"><title>Conclusion</title><p id="P4">These results suggest that the combination of cenersen with chemotherapy may have clinical efficacy and additional studies are warranted to explore its full potential.</p></sec></abstract><kwd-group><kwd>acute myeloid leukemia</kwd><kwd>refractory</kwd><kwd>relapsed</kwd><kwd>p53</kwd><kwd>antisense</kwd><kwd>cenersen</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>